Published in Cell on August 13, 1993
The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J (1994) 4.29
A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1997) 3.20
PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci U S A (2002) 3.19
The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML. EMBO J (1995) 2.93
PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol Cell Biol (1994) 2.68
High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. J Clin Invest (2009) 2.66
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood (2011) 2.59
Circuitry and dynamics of human transcription factor regulatory networks. Cell (2012) 2.56
Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1997) 2.54
Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci U S A (1997) 2.47
Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest (2003) 2.12
Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol (2004) 1.96
Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med (1999) 1.91
Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci U S A (1999) 1.88
Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling. Proc Natl Acad Sci U S A (1999) 1.82
Activation of gene expression by herpes simplex virus type 1 ICP0 occurs at the level of mRNA synthesis. J Virol (1997) 1.72
The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Mol Cell Biol (2001) 1.70
The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein. Mol Cell Biol (1998) 1.69
In vitro assembly of a functional human CDK7-cyclin H complex requires MAT1, a novel 36 kDa RING finger protein. EMBO J (1995) 1.66
Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood (2009) 1.61
ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood (2005) 1.59
BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia. J Exp Med (2001) 1.47
CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment. J Clin Invest (1999) 1.45
PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. J Exp Med (2004) 1.34
Transgenic expression of PML/RARalpha impairs myelopoiesis. Proc Natl Acad Sci U S A (1996) 1.31
Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip. Blood (2007) 1.28
Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains. EMBO J (1996) 1.27
Growth inhibition and induction of differentiation of t(8;21) acute myeloid leukemia cells by the DNA-binding domain of PEBP2 and the AML1/MTG8(ETO)-specific antisense oligonucleotide. Proc Natl Acad Sci U S A (1994) 1.27
PML suppresses oncogenic transformation of NIH/3T3 cells by activated neu. J Exp Med (1995) 1.26
PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol (1999) 1.25
Inhibition of long non-coding RNA NEAT1 impairs myeloid differentiation in acute promyelocytic leukemia cells. BMC Cancer (2014) 1.23
Neutrophil elastase is important for PML-retinoic acid receptor alpha activities in early myeloid cells. Mol Cell Biol (2005) 1.21
Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling. Mol Cell Biol (1997) 1.12
Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues. Am J Pathol (1996) 1.11
Active repression by unliganded retinoid receptors in development: less is sometimes more. J Cell Biol (2003) 1.08
A retrovirus carrying the promyelocyte-retinoic acid receptor PML-RARalpha fusion gene transforms haematopoietic progenitors in vitro and induces acute leukaemias. EMBO J (1996) 1.08
Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor alpha (CBFalpha) subunit by the leukemia-related PEBP2/CBFbeta-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation. Mol Cell Biol (1998) 1.06
Cell death induction by the acute promyelocytic leukemia-specific PML/RARalpha fusion protein. Proc Natl Acad Sci U S A (1997) 1.02
PML-RARA can increase hematopoietic self-renewal without causing a myeloproliferative disease in mice. J Clin Invest (2011) 1.00
Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein. Mol Cell Biol (2006) 0.99
DNA recognition by the aberrant retinoic acid receptors implicated in human acute promyelocytic leukemia. Cell Growth Differ (2001) 0.99
Topoisomerase IIbeta negatively modulates retinoic acid receptor alpha function: a novel mechanism of retinoic acid resistance. Mol Cell Biol (2008) 0.98
Btg2 enhances retinoic acid-induced differentiation by modulating histone H4 methylation and acetylation. Mol Cell Biol (2006) 0.97
Leukemic transformation by the v-ErbA oncoprotein entails constitutive binding to and repression of an erythroid enhancer in vivo. EMBO J (1998) 0.97
Curing all patients with acute promyelocytic leukemia: are we there yet? Hematol Oncol Clin North Am (2011) 0.96
Retinoid differentiation therapy for common types of acute myeloid leukemia. Leuk Res Treatment (2012) 0.94
Immune evasion by oncogenic proteins of acute myeloid leukemia. Blood (2014) 0.94
Advanced prostate cancer--a case for adjuvant differentiation therapy. Nat Rev Urol (2012) 0.93
Tetrandrine induces autophagy and differentiation by activating ROS and Notch1 signaling in leukemia cells. Oncotarget (2015) 0.91
ATRA-induced upregulation of Beclin 1 prolongs the life span of differentiated acute promyelocytic leukemia cells. Autophagy (2011) 0.90
Overexpression of the long non-coding RNA PVT1 is correlated with leukemic cell proliferation in acute promyelocytic leukemia. J Hematol Oncol (2015) 0.90
CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells. J Hematol Oncol (2014) 0.90
Daxx is a transcriptional repressor of CCAAT/enhancer-binding protein beta. J Biol Chem (2009) 0.90
PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia. Cancer Res (2015) 0.90
Dual effect of oxidative stress on leukemia cancer induction and treatment. J Exp Clin Cancer Res (2014) 0.88
Aberrant corepressor interactions implicated in PML-RAR(alpha) and PLZF-RAR(alpha) leukemogenesis reflect an altered recruitment and release of specific NCoR and SMRT splice variants. J Biol Chem (2010) 0.88
Synergistic decrease of clonal proliferation, induction of differentiation, and apoptosis of acute promyelocytic leukemia cells after combined treatment with novel 20-epi vitamin D3 analogs and 9-cis retinoic acid. J Clin Invest (1997) 0.87
PML-RARα enhances constitutive autophagic activity through inhibiting the Akt/mTOR pathway. Autophagy (2011) 0.86
Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells. EMBO J (2005) 0.85
Ectopic TAL-1/SCL expression in phenotypically normal or leukemic myeloid precursors: proliferative and antiapoptotic effects coupled with a differentiation blockade. Mol Cell Biol (1997) 0.85
The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts. J Clin Invest (1998) 0.84
Interaction with RXR is necessary for NPM-RAR-induced myeloid differentiation blockade. Leuk Res (2013) 0.81
Induction of the pro-myelocytic leukaemia gene by type I and type II interferons. Mediators Inflamm (1998) 0.80
Disseminated exfoliative dermatitis associated with all-transretinoic Acid in the treatment of acute promyelocytic leukemia. Case Rep Med (2012) 0.79
Disruption of the PHRF1 Tumor Suppressor Network by PML-RARα Drives Acute Promyelocytic Leukemia Pathogenesis. Cell Rep (2015) 0.79
PMLRARα binds to Fas and suppresses Fas-mediated apoptosis through recruiting c-FLIP in vivo. Blood (2011) 0.79
Auranofin promotes retinoic acid- or dihydroxyvitamin D3-mediated cell differentiation of promyelocytic leukaemia cells by increasing histone acetylation. Br J Pharmacol (2008) 0.78
Emerging new approaches for the treatment of acute promyelocytic leukemia. Ther Adv Hematol (2011) 0.78
Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia. Korean J Pediatr (2011) 0.78
Establishment of a humanized APL model via the transplantation of PML-RARA-transduced human common myeloid progenitors into immunodeficient mice. PLoS One (2014) 0.78
The lncRNA HOTAIRM1 regulates the degradation of PML-RARA oncoprotein and myeloid cell differentiation by enhancing the autophagy pathway. Cell Death Differ (2016) 0.78
MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells. Invest New Drugs (2009) 0.78
8-CPT-cAMP/all-trans retinoic acid targets t(11;17) acute promyelocytic leukemia through enhanced cell differentiation and PLZF/RARα degradation. Proc Natl Acad Sci U S A (2013) 0.77
The DNA binding property of PML/RARA but not the integrity of PML nuclear bodies is indispensable for leukemic transformation. PLoS One (2014) 0.77
Cooperation of cytokine signaling with chimeric transcription factors in leukemogenesis: PML-retinoic acid receptor alpha blocks growth factor-mediated differentiation. Mol Cell Biol (2003) 0.77
Expression of promyelocytic leukemia protein increases during the differentiation of human neuroblastoma cells. Virchows Arch (2003) 0.76
PML-RAR alpha induces the downmodulation of HHEX: a key event responsible for the induction of an angiogenetic response. J Hematol Oncol (2016) 0.76
Bleeding related to disturbed fibrinolysis. Br J Haematol (2016) 0.76
Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era. Mediterr J Hematol Infect Dis (2011) 0.76
Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1β. Ann Hematol (2017) 0.75
PML nuclear body disruption impairs DNA double-strand break sensing and repair in APL. Cell Death Dis (2016) 0.75
NLS‑RARα modulates acute promyelocytic leukemia NB4 cell proliferation and differentiation via the PI3K/AKT pathway. Mol Med Rep (2016) 0.75
Molecular basis for the diagnosis and treatment of acute promyelocytic leukemia. Rev Bras Hematol Hemoter (2012) 0.75
ΔNp73 overexpression promotes resistance to apoptosis but does not cooperate with PML/RARA in the induction of an APL-leukemic phenotype. Oncotarget (2016) 0.75
Acute promyelocytic leukemia with the translocation t(15;17)(q22;q21) associated with t(1;2)(q42~43;q11.2~12): a case report. J Med Case Rep (2016) 0.75
Biological functional annotation of retinoic acid alpha and beta in mouse liver based on genome-wide binding. Am J Physiol Gastrointest Liver Physiol (2014) 0.75
PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity. Oncotarget (2016) 0.75
A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods (1991) 16.64
Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ (2007) 8.08
A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell (1992) 6.86
Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 5.30
PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature (2000) 4.90
High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res (1998) 3.56
A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1997) 3.20
Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ (2006) 3.12
Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature (1999) 2.88
Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene (1991) 2.86
The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene (1995) 2.80
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst (1998) 2.75
Differential and stage-related expression in embryonic tissues of a new human homoeobox gene. Nature (1987) 2.42
Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood (1990) 2.40
The interplay between the master transcription factor PU.1 and miR-424 regulates human monocyte/macrophage differentiation. Proc Natl Acad Sci U S A (2007) 2.34
Formation of Shc-Grb2 complexes is necessary to induce neoplastic transformation by overexpression of Shc proteins. Oncogene (1994) 2.27
KDR receptor: a key marker defining hematopoietic stem cells. Science (1999) 2.13
Acute promyelocytic leukemia: from genetics to treatment. Blood (1994) 2.09
Circulating haemopoietic and endothelial progenitor cells are decreased in COPD. Eur Respir J (2006) 2.05
Acute perforation of colonic diverticula associated with short-term indomethacin. Lancet (1978) 1.94
Use of a two-hybrid assay to study the assembly of a complex multicomponent protein machinery: bacterial septosome differentiation. Microbiology (2003) 1.94
Genistein inhibits tumour cell growth in vitro but enhances mitochondrial reduction of tetrazolium salts: a further pitfall in the use of the MTT assay for evaluating cell growth and survival. Eur J Cancer (1993) 1.92
Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc Natl Acad Sci U S A (1991) 1.90
Distribution of T cells bearing different forms of the T cell receptor gamma/delta in normal and pathological human tissues. J Immunol (1989) 1.89
Haemoglobin switching in human embryos: asynchrony of zeta----alpha and epsilon----gamma-globin switches in primitive and definite erythropoietic lineage. Nature (1985) 1.87
Proteinase-activated receptor 2 is an anti-inflammatory signal for colonic lamina propria lymphocytes in a mouse model of colitis. Proc Natl Acad Sci U S A (2001) 1.84
Expression of platelet membrane glycoproteins and alpha-granule proteins by a human erythroleukemia cell line (HEL). EMBO J (1984) 1.82
Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases. Oncogene (2011) 1.79
Expression of caveolin-1 is required for the transport of caveolin-2 to the plasma membrane. Retention of caveolin-2 at the level of the golgi complex. J Biol Chem (1999) 1.79
Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol (1999) 1.77
HOX4 genes encode transcription factors with potential auto- and cross-regulatory capacities. EMBO J (1991) 1.70
The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein. Mol Cell Biol (1998) 1.69
Molecular mechanisms of human hemoglobin switching: selective undermethylation and expression of globin genes in embryonic, fetal, and adult erythroblasts. Proc Natl Acad Sci U S A (1983) 1.68
Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice. J Immunol (1997) 1.68
Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia (2005) 1.67
Erythropoietin alone induces erythroid burst formation by human embryonic but not adult BFU-E in unicellular serum-free culture. Blood (1989) 1.64
The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer (2003) 1.63
Increased allergen-specific, steroid-sensitive gamma delta T cells in bronchoalveolar lavage fluid from patients with asthma. Ann Intern Med (1996) 1.61
A "housekeeping" gene on the X chromosome encodes a protein similar to ubiquitin. Proc Natl Acad Sci U S A (1988) 1.60
Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms. Oncogene (1992) 1.59
Production of hemolymphopoietic cytokines (IL-6, IL-8, colony-stimulating factors) by normal human astrocytes in response to IL-1 beta and tumor necrosis factor-alpha. J Immunol (1992) 1.59
Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia (2009) 1.56
Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood (1999) 1.54
Growth- and tumor-promoting effects of deregulated BCL2 in human B-lymphoblastoid cells. Proc Natl Acad Sci U S A (1989) 1.51
Inhibition of insulin receptor binding by phorbol esters. Eur J Biochem (1982) 1.49
HOXB7: a key factor for tumor-associated angiogenic switch. Cancer Res (2001) 1.47
Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias. J Exp Med (1990) 1.47
Ultrastructural localization of lactoferrin and myeloperoxidase in human neutrophils by immunogold. Blood (1985) 1.47
Influence of trauma on initiation of Reiter's syndrome and ankylosing spondylitis. Ann Rheum Dis (1985) 1.45
Cell cycle-dependent initiation and lineage-dependent abrogation of GATA-1 expression in pure differentiating hematopoietic progenitors. Proc Natl Acad Sci U S A (1992) 1.45
Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood (1998) 1.45
Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. Br J Pharmacol (2007) 1.45
Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer (1995) 1.44
Two point mutations are responsible for G6PD polymorphism in Sardinia. Am J Hum Genet (1989) 1.42
[Unsatisfactory results of intradiscal injection of triamcinolone hexacetonide in the treatment of sciatica caused by intervertebral disk herniation]. Presse Med (1992) 1.42
Human embryonic hemopoiesis. Kinetics of progenitors and precursors underlying the yolk sac----liver transition. J Clin Invest (1986) 1.39
Optimal needle length of automatic injectors. Crit Care Med (1990) 1.38
Intrapericardial tetracycline sclerosis in the treatment of malignant pericardial effusion: an analysis of thirty-three cases. J Clin Oncol (1984) 1.36
HOXB7 constitutively activates basic fibroblast growth factor in melanomas. Mol Cell Biol (1996) 1.35
'Advanced' generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. Gene Ther (2003) 1.35
N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res (1993) 1.33
Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Ann Oncol (2001) 1.32
Growth-inhibitory effects of the natural phyto-oestrogen genistein in MCF-7 human breast cancer cells. Eur J Cancer (1994) 1.32
NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci U S A (2001) 1.31